Improving heart- and kidney-protective treatment for people with type 2 diabetes and chronic kidney disease
Closing the Cardio-Renal Preventive Treatment Gap Among Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: An Implementation Science Approach
This project will help people with type 2 diabetes and chronic kidney disease get proven medicines that protect the heart and kidneys but are often missed.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11303260 on NIH RePORTER |
What this research studies
The team will analyze VA medical records from over 1.5 million people with type 2 diabetes to identify patterns in who receives cardio-renal preventive medicines. They will hold focus groups with patients and healthcare providers to hear real-world barriers and reasons those medicines are under-prescribed. Combining these findings, the researchers will design and pilot implementation approaches to increase appropriate use of ACE inhibitors/ARBs, GLP-1 receptor agonists, and SGLT2 inhibitors. Early work is mentored and exploratory, then moves to independent testing of practical solutions in clinical settings.
Who could benefit from this research
Good fit: Adults with type 2 diabetes and chronic kidney disease, especially veterans receiving care in the VA system, are the ideal candidates to benefit from and participate in this work.
Not a fit: People without type 2 diabetes or without chronic kidney disease, or those already receiving optimal cardio-renal preventive therapy, are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, more people with type 2 diabetes and CKD could receive proven treatments that lower the risk of heart attacks and slow kidney decline.
How similar studies have performed: The medications targeted by this project have strong evidence for reducing cardiovascular and kidney risk, but implementation efforts to close prescription gaps are relatively new and still being developed.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Lamprea Montealegre, Julio Alejandro — University of California, San Francisco
- Study coordinator: Lamprea Montealegre, Julio Alejandro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.